Hillsdale Investment Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.21M | Sell |
20,698
-1,400
| -6% | -$301K | 0.12% | 225 |
|
|
2026
Q1 | $4.81M | Buy |
22,098
+6,730
| +44% | +$1.49M | 0.13% | 195 |
|
|
2025
Q4 | $3.51M | Buy |
15,368
+6,130
| +66% | +$1.4M | 0.1% | 279 |
|
|
2025
Q3 | $2.14M | Sell |
9,238
-8,770
| -49% | -$1.79M | 0.06% | 311 |
|
|
2025
Q2 | $3.34M | Buy |
18,008
+16,300
| +954% | +$3.03M | 0.12% | 220 |
|
|
2025
Q1 | $358K | Sell |
1,708
-920
| -35% | -$179K | 0.02% | 380 |
|
|
2024
Q4 | $467K | Buy |
2,628
+230
| +10% | +$42.3K | 0.02% | 355 |
|
|
2024
Q3 | $474K | Sell |
2,398
-984
| -29% | -$184K | 0.04% | 351 |
|
|
2024
Q2 | $580K | Buy |
3,382
+2,100
| +164% | +$348K | 0.05% | 299 |
|
|
2024
Q1 | $233K | Buy |
1,282
+50
| +4% | +$8.62K | 0.02% | 361 |
|
|
2023
Q4 | $191K | Buy |
1,232
+330
| +37% | +$48.1K | 0.02% | 363 |
|
|
2023
Q3 | $134K | Buy |
902
+470
| +109% | +$69K | 0.01% | 370 |
|
|
2023
Q2 | $58.2K | Sell |
432
-135
| -24% | -$19.8K | 0.01% | 403 |
|
|
2023
Q1 | $90.4K | Sell |
567
-3,622
| -86% | -$554K | 0.01% | 465 |
|
|
2022
Q4 | $677K | Sell |
4,189
-430
| -9% | -$65.9K | 0.06% | 257 |
|
|
2022
Q3 | $619K | Buy |
4,619
+181
| +4% | +$26K | 0.06% | 266 |
|
|
2022
Q2 | $681K | Buy |
4,438
+3,409
| +331% | +$521K | 0.05% | 254 |
|
|
2022
Q1 | $166K | Buy |
1,029
+113
| +12% | +$16.4K | 0.01% | 407 |
|
|
2021
Q4 | $124K | Sell |
916
-396
| -30% | -$46.8K | 0.01% | 428 |
|
|
2021
Q3 | $142K | Sell |
1,312
-130
| -9% | -$14.9K | 0.01% | 420 |
|
|
2021
Q2 | $162K | Sell |
1,442
-220
| -13% | -$24.8K | 0.01% | 416 |
|
|
2021
Q1 | $180K | Sell |
1,662
-5,460
| -77% | -$584K | 0.02% | 406 |
|
|
2020
Q4 | $763K | Sell |
7,122
-10
| -0.1% | -$961 | 0.07% | 259 |
|
|
2020
Q3 | $625K | Sell |
7,132
-120
| -2% | -$11.3K | 0.06% | 278 |
|
|
2020
Q2 | $712K | Sell |
7,252
-288
| -4% | -$25.4K | 0.06% | 262 |
|
|
2020
Q1 | $574K | Sell |
7,540
-350
| -4% | -$29.8K | 0.07% | 266 |
|
|
2019
Q4 | $699K | Buy |
7,890
+300
| +4% | +$24.9K | 0.06% | 291 |
|
|
2019
Q3 | $575K | Sell |
7,590
-460
| -6% | -$31.5K | 0.05% | 304 |
|
|
2019
Q2 | $586K | Buy |
8,050
+1,450
| +22% | +$114K | 0.06% | 299 |
|
|
2019
Q1 | $531K | Buy |
6,600
+1,365
| +26% | +$112K | 0.05% | 287 |
|
|
2018
Q4 | $483K | Hold |
5,235
| – | – | 0.06% | 217 |
|
|
2018
Q3 | $495K | Sell |
5,235
-1,600
| -23% | -$152K | 0.06% | 176 |
|
|
2018
Q2 | $633K | Buy |
6,835
+1,975
| +41% | +$193K | 0.08% | 177 |
|
|
2018
Q1 | $460K | Sell |
4,860
-700
| -13% | -$76.9K | 0.06% | 185 |
|
|
2017
Q4 | $539K | Hold |
5,560
| – | – | 0.09% | 185 |
|
|
2017
Q3 | $495K | Buy |
5,560
+750
| +16% | +$57.1K | 0.08% | 182 |
|
|
2017
Q2 | $349K | Buy |
4,810
+4,660
| +3,107% | +$313K | 0.07% | 221 |
|
|
2017
Q1 | $10K | Hold |
150
| – | – | ﹤0.01% | 342 |
|
|
2016
Q4 | $9K | Hold |
150
| – | – | ﹤0.01% | 353 |
|
|
2016
Q3 | $9K | Hold |
150
| – | – | ﹤0.01% | 381 |
|
|
2016
Q2 | $9K | Sell |
150
-9,000
| -98% | -$548K | ﹤0.01% | 389 |
|
|
2016
Q1 | $523K | Sell |
9,150
-550
| -6% | -$30.7K | 0.18% | 76 |
|
|
2015
Q4 | $575K | Buy |
+9,700
| New | +$559K | 0.22% | 63 |
|
Other funds holding ABBV
Hillsdale Investment Management's ABBV Position: Q2 2026 in Review
Hillsdale Investment Management reduced its AbbVie (ABBV) stake by 6.3% in Q2 2026, selling an estimated $301K and leaving 20,698 shares worth $5.21M. The position accounts for 0.12% of the portfolio, ranked #225.
Hillsdale Investment Management first reported a position in ABBV in Q4 2015 and has held it in 43 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Hillsdale Investment Management held 20,698 shares of AbbVie worth $5.21M as of Q2 2026.
- Hillsdale Investment Management sold 1,400 AbbVie shares in Q2 2026, an estimated $301K.
- AbbVie made up 0.12% of Hillsdale Investment Management's portfolio in Q2 2026, its #225 holding.
- Hillsdale Investment Management first reported a position in AbbVie in Q4 2015 and has held it in 43 quarters since.
- 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Hillsdale Investment Management's 13F filing for Q2 2026, filed 12 Aug 2026.